Clinical Trials Sponsored by Cellular Sciences

Total 19542 results

Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

Canada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
Gilead Sciences

Completed

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Spain, Puerto Rico, Australia, Thailand, Brazil, France, Belgium, Canada, Dominican Republic, United Kingdom, Germany, Netherlands, Italy, Austria, Denmark, Mexico, Portugal, Switzerland
Gilead Sciences

Completed

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Gilead Sciences

Completed

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Hepatitis B

Canada, Germany, Turkey, United States, Greece, New Zealand, Hungary, Romania, Bulgaria, Serbia, Austria, Poland, Czech Republic, Spain
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Gilead Sciences

Completed

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Chronic Hepatitis B

Taiwan, France, Germany, Hong Kong, United States, Canada, New Zealand, Australia, Singapore, Poland, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

HIV Infections

Brazil, Panama
Gilead Sciences

Completed

A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Gilead Sciences

Withdrawn

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Ischemic Heart Disease
Alimera Sciences

Terminated

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Age-Related Macular Degeneration

United States
Alimera Sciences

Terminated

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina (FAVOR)

Macular Edema | Retinal Vein Occlusion

United States
Gilead Sciences

Completed

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Long QT Syndrome

United States
Parion Sciences

Completed

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Hepatitis C | Human Immunodeficiency Virus

United States, Puerto Rico
Gilead Sciences

Completed

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA)

Coronary Artery Disease | Type 2 Diabetes Mellitus | Angina Pectoris

Canada, Slovenia, United States, Israel, Germany, Georgia, Russian Federation, Czech Republic, Belarus, Bulgaria, Poland, Serbia, Slovakia, Ukraine
Gilead Sciences

Completed

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

Ulcerative Colitis

New Zealand
Gilead Sciences

Completed

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Russian Federation, Serbia, Poland, Hungary, South Africa, Ukraine, Romania, Slovakia, Czech Republic
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

Hepatitis C

Spain, Netherlands, Austria, France, United Kingdom, Italy, Estonia, Germany, Poland, Sweden
Gilead Sciences

Completed

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Type 2 Diabetes Mellitus

United States, Russian Federation, Israel, South Africa, India, Hungary, Ukraine, Canada, Czech Republic, Mexico, Poland
Gilead Sciences

Completed

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

Cystic Fibrosis

United States
Gilead Sciences

Terminated

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Coronary Artery Disease | Pain | Peripheral Nervous System Diseases | Polyneuropathy

United States
Gilead Sciences

Completed

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NEUTRINO)

Chronic Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis (AIR-BX2)

Bronchiectasis

United States, Belgium, Spain, Canada, Australia, Germany, United Kingdom, Netherlands, France, Italy
Gilead Sciences

Completed

Phase 3 Study of Sofosbuvir and Ribavirin (FISSION)

Hepatitis C

United States, Australia, Canada, Puerto Rico, New Zealand, Sweden, Italy, Netherlands
Gilead Sciences

Completed

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Type 2 Diabetes Mellitus

United States
Gilead Sciences

Completed

Safety Study of Tecadenoson to Treat Atrial Fibrillation

Atrial Fibrillation

United States
Gilead Sciences

Completed

Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan

Hepatitis B

Taiwan
Gilead Sciences

Completed

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Terminated

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States, Czech Republic, Russian Federation
Gilead Sciences

Terminated

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Israel, Australia, Canada, Mexico, Spain, Belgium, Austria, Germany, United Kingdom
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Gilead Sciences

Terminated

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Chronic Hepatitis C

United States, Australia, Canada, New Zealand
Gilead Sciences

Terminated

Stress Echocardiography Study With Regadenoson

Coronary Artery Disease | Heart Disease

United Kingdom
Gilead Sciences

Completed

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

HIV Infections

United States
Gilead Sciences

Completed

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

Healthy Volunteers

United States
Gilead Sciences

Completed

Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.

Hepatitis B
Gilead Sciences

Approved for marketing

An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options

Chronic Hepatitis B
Gilead Sciences

Terminated

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension (Darusentan)

Hypertension

United States, Argentina, Australia, Brazil
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Withdrawn

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

Australia
Gilead Sciences

Completed

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Diabetes Mellitus, Type 2

United States
Gilead Sciences

Completed

Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.

HIV Infections
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

Glioblastoma Multiforme

Australia
Gilead Sciences

Completed

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Chronic Hepatitis B

United States, Canada, Spain, Singapore, Turkey, Germany, France, Taiwan, Greece, Italy, Poland

3

Subscribe